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ABSTRACT 
Background: Standard treatment of cobalamin (vitamin Bl2 ) deficiency in- 
volves regular (1000 pg/mo) IM cyanocobalamin administration. It has been 
suggested that high-dose (>2000 pg/d) oral cyanocobalamin may be effective in 
patients with pernicious anemia. 
Objective: The aim of this study was to assess the efficacy and tolerability 
of oral crystalline cyanocobalamin 1000 pg/d in patients with cobalamin defi- 
ciency related to established pernicious anemia. 
Methods: This open-label, prospective study was conducted at Strasbourg 
University Hospital, Strasbourg, France. Patients aged _>18 years with well- 
documented cobalamin deficiency related to pernicious anemia were enrolled. 
Patients received crystalline cyanocobalamin 1000 pg QD PO (capsule) for at 
least 3 months. Serum cobalamin, folate, iron, and homocysteine concentra- 
tions were measured, and a complete blood count was obtained, before (month 0; 
baseline) and after treatment. 
Results: Ten patients (7 women, 3 men; mean [SD] age, 72.1 [15.5] years) en- 
tered the study. After 3 months of treatment, serum cobalamin concentration 
increased in all 9 patients in whom it was measured (mean [SD] increase, 117.4 
[30.8] pg/mL; P < 0.001 vs baseline). Serum cobalamin concentrations were nor- 
malized (>200 pg/mL) in 6 patients. The serum cobalamin concentration was 
unavailable in 1 patient because of technical problems. Eight patients had 
increased hemoglobin concentrations (mean [SD] increase, 2.5 [2.4] g/dL; P < 
0.01 vs baseline). All 10 patients had decreased mean erythrocyte corpuscular 
volumes (mean [SD] decrease, 10.4 [6.2] IL; P < 0.003 vs baseline). Four patients 
received concomitant blood transfusions or lolate and iron supplementation. 
Three patients experienced clinical improvement in paresthesia, reflex aboli- 
tion, or combined medullary sclerosis (each, 1 patient). 
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Condusion: The results of this small study in patients with cobalamin defi- 
ciency related to pernicious anemia suggest hat oral crystalline cyanocobala- 
min 1000 IJg/d may be an effective treatment. (Curr Ther Res Clin Exp. 2005;66: 
13-22) Copyright © 2005 Excerpta Medica, Inc. 
Key words: cobalamin deficiency, pernicious anemia, oral cyanocobalamin 
treatment. 
INTRODUCTION 
Approximately 15% of people aged >60 years in the United States are thought o 
have undiagnosed cobalamin (vitamin B12 ) deficiency. 1 The most common causes, 
particularly in elderly (aged _>65 years) patients, are cobalamin malabsorption from 
food and pernicious anemia (Addison-Biermer anemia). 2,3 Pernicious anemia is a 
chronic illness caused by impaired absorption of cobalamin due to intrinsic factor 
deficiency. 3,4 Two mechanisms are responsible. First, the progressive destruction 
and eventual loss of parietal cells from the gastric mucosa lead to failure of intrin- 
sic factor production. 4 Second, blocking autoantibodies in the bile can bind to the 
cobalamin binding site of intrinsic factor, thereby preventing the formation of the 
cobalamin--intrinsic factor complex. 4 Standard treatment of cobalamin deficiency 
involves regular (1000 pg/mo) IM cyanocobalamin jections. It has been sug- 
gested that high-dose (>2000 pg/d) oral cyanocobalamin therapy may be ef- 
fective for cobalamin deficiency, ~ but rarely in established pernicious ane- 
mia. However, the utility of the 1000-pg/d ose was previously documented in 
3 patients at Strasbourg University Hospital, Strasbourg, France. G,7 
Based on a MEDLINE search (key terms: cobalamin deficiency and treatment 
and vitamin B12 deficiency and treatment; years: 1966-2004), currently, only case 
reports e,7 and studies with poorly determined or undetermined causes of co- 
balamin deficiency e,9 have been published. Thus, we studied the efficacy and 
tolerability of oral crystalline cyanocobalamin 1000 pg/d in patients with co- 
balamin deficiency related to established pernicious anemia. 
PATIENTS AND METHODS 
Patient Selection 
Patients aged 218 years were recruited from the Departments of Internal 
Medicine, Diabetes and Metabolic Disorders, Hematology, Nutrition, and 
Geriatrics, Strasbourg University Hospital, between February 1998 and 
September 2003. Patients underwent a clinical examination, including the 
Schilling test, 1° to establish a diagnosis of pernicious anemia. Urine samples 
were then collected over 24 hours (from day 2 to day 3), and the percentage 
of labeled cyanocobalamin was determined (<6%). To be included in this 
open-label, prospective study, patients met the following criteria: (1) serum 
cobalamin concentration <200 pg/mL confirmed on 2 serum samples or in as- 
sociation with a homocysteine concentration >13 IJmol/L 11,12 and (2) evidence 
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of serum antibodies to intrinsic [actor 4that established the diagnosis of perni- 
cious anemia, n,12 The Schilling test was performed as follows: patients were 
administered cyanocobalamin 1000 pg IM on day 1, and 1000 IJg cyanocobala- 
min free of s7CO-cobalamin PC) on day 2. 
Patients were excluded if they were unable to follow a physician's directives 
or take oral medication, had a severe associated condition (eg, cardiac or res- 
piratory failure, liver failure, inflammatory bowel disease), or had a history of 
malignancy or hypersensitivity o cobalamin. Folate and iron deficiencies were 
not exclusion criteria. Pregnant, possibly pregnant, or breastfeeding women 
were excluded from the study. 
All eligible patients provided verbal informed consent o participate. An in- 
stitutional review board (the Cobalamin Deficiency Study Group at Strasbourg 
University Hospital) approved the study protocol. 
Study Procedures 
Crystalline cyanocobalamin* 1000 pg QD PC) (capsule) was self-administered 
for at least 3 months. Serum samples were obtained before (month 0; baseline) 
and after 3 months of treatment. Serum cobalamin, folate, iron, and homocys- 
teine concentrations were measured, and a complete blood count was obtained. 
The primary efficacy end point was normalization of serum cobalamin concen- 
tration (>200 pg/mL). Secondary end points involved reversal of blood count 
abnormalities (hemoglobin [Hb] concentration, >12 g/dL; mean erythrocyte cor- 
puscular volume [ECV], <100 fL; platelet count, >150 x 109 cells/L). Improvement 
in clinical findings 0ncluding neuropsychiatric status) was not considered an 
end point, given the difficulty of correlating clinical features with cobalamin de- 
ficiency (particularly in elderly patients) and with the severity of cobalamin 
deficiency.3,13 
Tolerability was assessed by recording adverse effects identified using pa- 
tient interview and laboratory analysis, including hematology, biochemistry, 
and liver and kidney function tests. 
Laboratory Analysis 
An automated Coulter counter (Technikon H1, Bayer HealthCare, Diag- 
nostics Division, Tarrytown, New York) was used to measure hematolog- 
ic variables. Serum cobalamin and folate concentrations were determined 
by enzyme immunoassay using a commercially available kit (Abbott Di- 
agnostics, Rungis, France). The total serum homocysteine l vel was mea- 
sured using capillary gas chromatography-mass spectrometry. Serum anti- 
intrinsic factor antibodies were determined by enzyme-linked immunosorbent 
assay using a commercially available kit (Bayer HeaithCare, Diagnostics 
Division). 
*Trademark: Vitamine B12 ® (Mille Delagrange Synthelabo, Meudon-la-For&t, France, or Aguettan, Lyon, 
France). 
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Statistical Analysis 
Pretreatment and posttreatment values were compared using the Student 
test for paired data. P < 0.05 was considered statistically significant. Data are 
expressed as mean (SD). StatView version 4.0 (SAS Institute Inc., Cary, North 
Carolina) was used for statistical analysis. 
RESULTS 
Of the 32 patients diagnosed with pernicious anemia during the recruit- 
ment period, 22 were excluded for the following reasons: concomitant life- 
threatening conditions (8 patients); inability to follow physician's directives (5); 
refusal to participate (5); and residing outside the immediate geographic area 
of Strasbourg University Hospital, thereby impeding adequate follow-up (4). 
The remaining 10 patients entered the study, 3 of whom had an absolute con- 
traindication to IM cyanocobalamin therapy because they were receiving anti- 
coagulant treatment. 
Pat ient  Character i s t i cs  
All 10 patients (7 women, 3 men; mean [SD] age, 72.1 [ 15.5] years) were white 
(Table I). All patients met the criteria for pernicious anemia with evidence of 
intrinsic factor antibodies. The Schilling test showed malabsorption with crys- 
talline ~TCO-cobalamin 3 patients. Immune gastric atrophy was observed in 
all 4 of the patients who underwent upper gastrointestinal endoscopy. All 10 
patients had documented cobalamin deficiency. The mean (SD) pretreatment 
serum cobalamin concentration was 106.5 (30.5) pg/mL; homocysteine, 18.2 
(3.4) pmol/L; and Hb, 9.2 (2.7) g/dL. Mean folate levels and iron status were nor- 
mal except in 3 patients, who were treated with [<)late and iron supplementa- 
tion. Two patients had diabetes mellitus, 4 had hypertension, and 1 had moder- 
ate renal failure. 
Treatment Response 
After 3 months of treatment, serum cobalamin concentrations were mea- 
sured in 9 patients, all of whom had increased concentrations compared with 
baseline (mean [SD] increase, 117.4 [30.8] pg/mL; P< 0.001). Serum cobalamin 
concentrations were normalized in 6 patients (Table II). Posttherapeutic 
serum cobalamin concentration was not available in 1 patient because of tech- 
nical problems. Eight patients had increased Hb concentrations (mean [SD] 
increase, 2.5 [2.4] g/dL; P < 0.01), and Hb concentrations were normalized in 
6 patients. 
Four patients received concomitant blood transfusions or [<)late and iron sup- 
plementation. If 2 patients were excluded from this analysis because they 
received blood transfusions, the mean increase in Hb concentration was 1.5 
(2.0) g/dL (P < 0.043). All 10 patients had decreased mean ECV (mean [SD] 
decrease, 10.4 [6.2] fL; P < 0.003 vs baseline), and the mean value was normalized 
16 
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Table II. Laboratory values before (month  O; baseline) and after 3 months of treat- 
ment with  oral crystall ine cyanocobalamin 1000 pg/d. 
Serum Cobalamin 
Concentration, pg/mL Hb, g/dL ECV, fL 
Patient 
No. Before After Before After Before After 
1 97 230 6.8 12.3* 111 99* 
2 56 180 7.4 12.1 t 109 86 t 
3 142 270 11.7 12.0 95 91 
4 120 260* 5.2 11.7* 114 98* 
5 100 190 8.0 9.4 112 102 
6 60 120 10.0 12.8* 102 87* 
7 110 ND 7.7 10.2" 93 85* 
8 110 202 9.6 10.7 98 94 
9 120 250 1 3.1 12.9 106 98 
10 150 310 12.9 12.8 92 88 
Mean (SD) 106.5 (30.5) 223.6 (56.9)§ 9.2 (2.7) 11.7 (1.2)1 103.2 (8.3) 92.8 (6.2)~ 
Hb = hemoglobin concentration; FCV = mean en]throcyte corpuscular volume; ND = not determined. 
*This patient was treated with folate and iron supplementation. 
tThis patient was initially treated with a blood transfusion (2 U). 
~This patient was initially treated with a blood transfusion (4 U). 
§P < 0.001 versus baseline. 
Ip < 0.01 versus baseline. 
Ip < 0.043 versus baseline. 
in 9 patients (Table II). Platelet counts normalized in all 3 patients with throm- 
bocytopenia. Serum homocysteine l vels were measured in 3 patients, all of 
whom had decreased levels compared with baseline (mean [SD] decrease, 1.2 
[0.7] pmol/L; P = 0.047). Three patients experienced clinical improvements in 
paresthesia, reflex abolition, or combined medullary sclerosis (each, 1 patient). 
Compliance and Tolerabil ity 
All 10 patients reported being fully compliant with the study medication, 
although compliance was not systematically studied. One patient experienced 
transient localized urticarial eruption after 2 months of cyanocobalamin therapy. 
During the eruption, the patient also was receiving ampicillin for a sore throat. 
DISCUSSION 
The results of this open-label study suggest hat patients with established 
cobalamin deficiency related to pernicious anemia generally benefit from crys- 
talline cyanocobalamin 1000 pg QD PO. These results may be of particular inter- 
est in patients with contraindications to IM cyanocobalamin (eg, concomitant 
anticoagulant therapy). ]4
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All patients had well-documented pernicious anemia with evidence of intrin- 
sic factor antibodies, which had a specificity >98% (sensitivity, >50%), 3,1~ and 
cobalamin deficiency, n 12,1G,17 Nine of the 10 patients had blood abnormalities: 
anemia, macrocytosis, thrombocytopenia, or thrombotic microangiopathy s n- 
drome (indicated by evidence of schistocytes), all of which are late findings in 
cobalamin deficiency. 14,1a,19 
All patients who were tested showed improvements in serum cobalamin con- 
centrations and hematologic abnormalities. Serum cobalamin concentrations 
were normalized in 6 patients. In 1 patient, follow-up cobalamin concentrations 
were not measured because of technical problems; this patient had a major 
improvement in Hb concentration. Two patients were given blood transfusions 
(2 and 4 lY), which provided 1.25 and 2.50 g, respectively, of cobalamin. All ane- 
mic patients had improvements in their Hb concentration, even in the case of 
severe anemia (Hb concentration, <8 g/dL). In 4 patients, these improvements 
were also due to additional therapy: blood transfusion and folate and iron supple- 
mentation. We could not rule out the possibility that these additional thera- 
pies provided a false-positive response of oral cyanocobalamin therapy. Three 
patients also received IM cyanocobalamin for the Schilling test, but we have 
previously demonstrated that this does not interfere with increased cobalamin 
concentrations. 20 
These results are consistent with those observed in larger studies that used 
enteral cyanocobalamin, a,2°-23 However, the larger studies used higher doses of 
cyanocobalamin and/or included patients without a well-determined cause of 
cobalamin deficiency. In a randomized trial of 18 patients that included patients 
with pernicious anemia, a 4 months of treatment with oral cyanocobalamin 
2000 IJg/d led to improvements in hematocrit, mean ECV, and cobalamin con- 
centration in half of the treated patients. In another andomized study, Bolaman 
et al 9 reported similar effectiveness of oral (1000 IJg/d) and IM (1000 lJg/mo) 
cyanocobalamin therapy in 60 patients, including 8 patients with pernicious 
anemia. After 3 months of treatment, hey reported significant improvements in 
all hematologic parameters and cobalamin concentrations. Kondo 22 reported 
similar benefits with massive doses (>10,000 IJg/wk) of oral cyanocobalamin. 
These results are also consistent with several observations reported previously. 6,7 
In these patients, cobalamin deficiency related to pemicious anemia was resolved 
with oral cyanocobalamin 1000 l lg/dfl '7 
Only 3 patients in the present study reported clinical improvement, although 
1 patient had total regression of combined medullary sclerosis. The results of 
the present study are similar to those from the study by Kuzminski et al, a in 
which neuroiogic symptoms (eg, paresthesias) improved in only 4 of 18 patients. 
Bolaman et al 9 reported neurologic improvement in 7 of 9 symptomatic patients. 
In our study, the lack of clinical improvement may have been related to the 
short duration of treatment and follow-up. 24,2s Moreover, several neuroiogic 
manifestations of cyanocobalamin therapy were nonregressive despite a well- 
documented, effective therapy. 2G,27 Some of the clinical findings in the present 
19 
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study may also have been the result of age (mean [SD] age, 72.1 [15.5] years) or 
other underlying disorders (eg, diabetes). 
The results of the present study support hose from a study of the usefulness 
of oral crystalline cyanocobalamin food-cobalamin malabsorption, 25 a dis- 
order characterized by normal absorption of free cobalamin (malabsorption of
bound cobalamin). 27,2a These results (the effectiveness of oral cyanocobalamin 
therapy) may be related to the existence of a mechanism of simple diffusion, 
independent of intrinsic factor and cubulin, that permits absorption of a variable 
percentage of oral cyanocobalamin, 3,~,15,29 even in the case of intrinsic factor 
deficiency (the failure of intrinsic factor production and the presence of block- 
ing intrinsic factor antibodies), as in pernicious anemia. 3,4 Studies in volunteers 
have demonstrated that -1% to 5% of a large dose of oral cyanocobalamin s 
absorbed via this mechanism. 3,15 Although results suggest hat oral crystalline 
cyanocobalamin may be effective for the treatment of pernicious anemia, ~-9,21-23 
the ideal dose remains to be determined. 5,3°,31 The patients in the present study 
received 1000 pg/d of crystalline cyanocobalamin, with good efficacy. Kuzminski 
et al a studied a higher close of cyanocobalamin (2000 pg/d), with no increased 
benefit. Three of the patients in the present study had posttreatment cobala- 
min concentrations <200 pg/mL. One explanation may be the use of low-dose 
cyanocobalamin (perhaps 2000 pg/d may be more effective) or poor compliance 
with oral therapy, which was not systematically assessed in this study. 
This study was limited by its small sample size, relatively short treatment 
period (at least 3 months), the absence of randomization of a control group, 
and by the fact that 4 patients received concomitant blood transfusions or 
folate and iron supplementation. Nonetheless, given the apparent effective- 
ness of oral therapy and its possible benefits, including better compliance 
compared with IM treatment, or interest in patients who had an absolute con- 
traindication for IM cyanocobalamin (eg, concomitant anticoagulation therapy), 
further studies with larger sample sizes that use different cyanocobalamin doses 
are warranted. 
CONCLUSION 
The results of this small study in patients with cobalamin deficiency related to 
pernicious anemia suggest that oral crystalline cyanocobalamin 1000 pg/d may 
be an effective treatment. 
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